Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Z3TJ
|
|||
Former ID |
DIB019947
|
|||
Drug Name |
GSK2033
|
|||
Synonyms |
GSK 2033; GSK-2033
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C29H28F3NO5S2
|
|||
Canonical SMILES |
CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)CC4=CC=C(O4)C(F)(F)F)C
|
|||
InChI |
1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3
|
|||
InChIKey |
PSOXOVKYGWBTPB-UHFFFAOYSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Antagonist | [2] |
Oxysterols receptor LXR-beta (NR1H2) | Target Info | Antagonist | [2] | |
KEGG Pathway | PPAR signaling pathway | |||
Non-alcoholic fatty liver disease (NAFLD) | ||||
Hepatitis C | ||||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
Reactome | Nuclear Receptor transcription pathway | |||
WikiPathways | SREBP signalling | |||
Nuclear Receptors | ||||
Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
Nuclear Receptors Meta-Pathway | ||||
PPAR Alpha Pathway | ||||
Liver X Receptor Pathway | ||||
Adipogenesis | ||||
SREBF and miR33 in cholesterol and lipid homeostasis |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8690). | |||
REF 2 | Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.